Financhill
Sell
29

FOLD Quote, Financials, Valuation and Earnings

Last price:
$6.04
Seasonality move :
20.05%
Day range:
$5.89 - $6.15
52-week range:
$5.81 - $12.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.39x
P/B ratio:
9.59x
Volume:
4.2M
Avg. volume:
5M
1-year change:
-40.34%
Market cap:
$1.9B
Revenue:
$528.3M
EPS (TTM):
-$0.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FOLD
Amicus Therapeutics
$136.3M $0.08 16.44% -80% $15.82
AGIO
Agios Pharmaceuticals
$9.7M -$1.76 10.66% -6.63% $51.71
ALNY
Alnylam Pharmaceuticals
$581.2M -$0.37 -5.16% -5.09% $320.88
BPMC
Blueprint Medicines
$156.9M -$0.44 24.15% -36.72% $126.87
RARE
Ultragenyx Pharmaceutical
$144.5M -$1.64 9.48% -13.24% $89.84
VRTX
Vertex Pharmaceuticals
$2.9B $4.29 9.9% 1.98% $500.12
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FOLD
Amicus Therapeutics
$6.03 $15.82 $1.9B -- $0.00 0% 3.39x
AGIO
Agios Pharmaceuticals
$35.75 $51.71 $2.1B 3.18x $0.00 0% 55.87x
ALNY
Alnylam Pharmaceuticals
$308.78 $320.88 $40.3B -- $0.00 0% 16.90x
BPMC
Blueprint Medicines
$127.96 $126.87 $8.3B -- $0.00 0% 14.59x
RARE
Ultragenyx Pharmaceutical
$37.49 $89.84 $3.5B -- $0.00 0% 5.94x
VRTX
Vertex Pharmaceuticals
$455.45 $500.12 $117B 26.10x $0.00 0% 10.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FOLD
Amicus Therapeutics
66.87% -0.309 15.55% 2.22x
AGIO
Agios Pharmaceuticals
-- 3.909 -- 17.12x
ALNY
Alnylam Pharmaceuticals
89.88% 1.909 2.91% 2.84x
BPMC
Blueprint Medicines
53.13% 2.155 6.79% 2.62x
RARE
Ultragenyx Pharmaceutical
-- 0.723 -- 2.03x
VRTX
Vertex Pharmaceuticals
-- -0.242 -- 2.12x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FOLD
Amicus Therapeutics
$113.6M -$8M -5.29% -17.7% -5.26% $7.5M
AGIO
Agios Pharmaceuticals
$7.6M -$106.6M 55.14% 55.14% -1221.97% -$112.3M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
BPMC
Blueprint Medicines
$146.6M -$41.1M -23.09% -49.13% 12.78% -$56.3M
RARE
Ultragenyx Pharmaceutical
$110.6M -$142.9M -205.06% -205.06% -97.23% -$182.8M
VRTX
Vertex Pharmaceuticals
$2.4B $1B -6.04% -6.04% 26.48% $778.2M

Amicus Therapeutics vs. Competitors

  • Which has Higher Returns FOLD or AGIO?

    Agios Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -1023.25%. Amicus Therapeutics's return on equity of -17.7% beat Agios Pharmaceuticals's return on equity of 55.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
    AGIO
    Agios Pharmaceuticals
    87.57% -$1.55 $1.5B
  • What do Analysts Say About FOLD or AGIO?

    Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $51.71 which suggests that it could grow by 44.66%. Given that Amicus Therapeutics has higher upside potential than Agios Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Agios Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    FOLD
    Amicus Therapeutics
    8 3 0
    AGIO
    Agios Pharmaceuticals
    3 3 0
  • Is FOLD or AGIO More Risky?

    Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.155%.

  • Which is a Better Dividend Stock FOLD or AGIO?

    Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FOLD or AGIO?

    Amicus Therapeutics quarterly revenues are $125.2M, which are larger than Agios Pharmaceuticals quarterly revenues of $8.7M. Amicus Therapeutics's net income of -$21.7M is higher than Agios Pharmaceuticals's net income of -$89.3M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 3.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 55.87x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FOLD
    Amicus Therapeutics
    3.39x -- $125.2M -$21.7M
    AGIO
    Agios Pharmaceuticals
    55.87x 3.18x $8.7M -$89.3M
  • Which has Higher Returns FOLD or ALNY?

    Alnylam Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -9.67%. Amicus Therapeutics's return on equity of -17.7% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About FOLD or ALNY?

    Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.88 which suggests that it could grow by 3.92%. Given that Amicus Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    FOLD
    Amicus Therapeutics
    8 3 0
    ALNY
    Alnylam Pharmaceuticals
    12 7 1
  • Is FOLD or ALNY More Risky?

    Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.218, suggesting its less volatile than the S&P 500 by 78.213%.

  • Which is a Better Dividend Stock FOLD or ALNY?

    Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FOLD or ALNY?

    Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Amicus Therapeutics's net income of -$21.7M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 16.90x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FOLD
    Amicus Therapeutics
    3.39x -- $125.2M -$21.7M
    ALNY
    Alnylam Pharmaceuticals
    16.90x -- $594.2M -$57.5M
  • Which has Higher Returns FOLD or BPMC?

    Blueprint Medicines has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 0.33%. Amicus Therapeutics's return on equity of -17.7% beat Blueprint Medicines's return on equity of -49.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
    BPMC
    Blueprint Medicines
    98.13% $0.01 $729.9M
  • What do Analysts Say About FOLD or BPMC?

    Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -0.85%. Given that Amicus Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Amicus Therapeutics is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    FOLD
    Amicus Therapeutics
    8 3 0
    BPMC
    Blueprint Medicines
    2 15 1
  • Is FOLD or BPMC More Risky?

    Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.895%.

  • Which is a Better Dividend Stock FOLD or BPMC?

    Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FOLD or BPMC?

    Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Amicus Therapeutics's net income of -$21.7M is lower than Blueprint Medicines's net income of $496K. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 14.59x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FOLD
    Amicus Therapeutics
    3.39x -- $125.2M -$21.7M
    BPMC
    Blueprint Medicines
    14.59x -- $149.4M $496K
  • Which has Higher Returns FOLD or RARE?

    Ultragenyx Pharmaceutical has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -108.46%. Amicus Therapeutics's return on equity of -17.7% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
    RARE
    Ultragenyx Pharmaceutical
    79.42% -$1.57 $151.2M
  • What do Analysts Say About FOLD or RARE?

    Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 139.64%. Given that Amicus Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Amicus Therapeutics is more attractive than Ultragenyx Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    FOLD
    Amicus Therapeutics
    8 3 0
    RARE
    Ultragenyx Pharmaceutical
    13 1 0
  • Is FOLD or RARE More Risky?

    Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

  • Which is a Better Dividend Stock FOLD or RARE?

    Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FOLD or RARE?

    Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Amicus Therapeutics's net income of -$21.7M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 5.94x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FOLD
    Amicus Therapeutics
    3.39x -- $125.2M -$21.7M
    RARE
    Ultragenyx Pharmaceutical
    5.94x -- $139.3M -$151.1M
  • Which has Higher Returns FOLD or VRTX?

    Vertex Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 23.33%. Amicus Therapeutics's return on equity of -17.7% beat Vertex Pharmaceuticals's return on equity of -6.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
    VRTX
    Vertex Pharmaceuticals
    86.9% $2.49 $16.5B
  • What do Analysts Say About FOLD or VRTX?

    Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 9.81%. Given that Amicus Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    FOLD
    Amicus Therapeutics
    8 3 0
    VRTX
    Vertex Pharmaceuticals
    14 14 1
  • Is FOLD or VRTX More Risky?

    Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

  • Which is a Better Dividend Stock FOLD or VRTX?

    Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FOLD or VRTX?

    Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Amicus Therapeutics's net income of -$21.7M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 10.63x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FOLD
    Amicus Therapeutics
    3.39x -- $125.2M -$21.7M
    VRTX
    Vertex Pharmaceuticals
    10.63x 26.10x $2.8B $646.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 4.61% over the past day.

Buy
79
DAVE alert for Jun 17

Dave [DAVE] is up 3.92% over the past day.

Buy
57
DAR alert for Jun 17

Darling Ingredients [DAR] is up 7.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock